Literature DB >> 24842100

Aerosolized bovine lactoferrin reduces lung injury and fibrosis in mice exposed to hyperoxia.

Hsiao-Ling Chen1, Chih-Ching Yen, Shih-Ming Wang, Tung-Chou Tsai, Zi-Lun Lai, Jheng-Yue Sun, Willei Lin, Wu-Huei Hsu, Chuan-Mu Chen.   

Abstract

This study investigated the ability of aerosolized bovine lactoferrin (bLF) to protect the lungs from injury induced by chronic hyperoxia. Female CD-1 mice were exposed to hyperoxia (FiO2 = 80 %) for 7 days to induce lung injury and fibrosis. The therapeutic effects of bLF, administered via an aerosol delivery system, on the chronic lung injury induced by this period of hyperoxia were measured by bronchoalveolar lavage, lung histology, cell apoptosis, and inflammatory cytokines in the lung tissues. After exposure to hyperoxia for 7 days, the survival of the mice was significantly decreased to 20 %. The protective effects of bLF against hyperoxia were further confirmed by significant reductions in lung edema, total cell numbers in bronchoalveolar lavage fluid, inflammatory cytokines (IL-1β and IL-6), pulmonary fibrosis, and apoptotic DNA fragmentation. The aerosolized bLF protected the mice from oxygen toxicity and increased the survival fraction to 66.7 % in the hyperoxic model. The results support the use of an aerosol therapy with bLF in intensive care units to reduce oxidative injury in patients with severe hypoxemic respiratory failure or chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24842100     DOI: 10.1007/s10534-014-9750-7

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  8 in total

1.  5-aza-2'-deoxycytidine, a DNA methylation inhibitor, attenuates hyperoxia-induced lung fibrosis via re-expression of P16 in neonatal rats.

Authors:  Shi-Meng Zhao; Hong-Min Wu; Mei-Ling Cao; Dan Han
Journal:  Pediatr Res       Date:  2017-12-20       Impact factor: 3.756

2.  Lactoferrin Protects Hyperoxia-Induced Lung and Kidney Systemic Inflammation in an In Vivo Imaging Model of NF-κB/Luciferase Transgenic Mice.

Authors:  Chih-Ching Yen; Wen-Hui Chang; Min-Che Tung; Hsiao-Ling Chen; Hsu-Chung Liu; Chun-Huei Liao; Ying-Wei Lan; Kowit-Yu Chong; Shang-Hsun Yang; Chuan-Mu Chen
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 3.  Lactoferrin: from the structure to the functional orchestration of iron homeostasis.

Authors:  Giusi Ianiro; Luigi Rosa; Maria Carmela Bonaccorsi di Patti; Piera Valenti; Giovanni Musci; Antimo Cutone
Journal:  Biometals       Date:  2022-10-10       Impact factor: 3.378

4.  Using Dual Fluorescence Reporting Genes to Establish an In Vivo Imaging Model of Orthotopic Lung Adenocarcinoma in Mice.

Authors:  Cheng-Wei Lai; Hsiao-Ling Chen; Chih-Ching Yen; Jiun-Long Wang; Shang-Hsun Yang; Chuan-Mu Chen
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

Review 5.  Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances.

Authors:  Md Sarwar Zahan; Kazi Ahsan Ahmed; Akhi Moni; Alessandra Sinopoli; Hunjoo Ha; Md Jamal Uddin
Journal:  Korean J Physiol Pharmacol       Date:  2022-01-01       Impact factor: 2.016

6.  Lung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.

Authors:  Yu-Tang Tung; Pin-Wu Huang; Yu-Ching Chou; Cheng-Wei Lai; Hsiu-Po Wang; Heng-Chien Ho; Chih-Ching Yen; Chih-Yen Tu; Tung-Chou Tsai; Dah-Cherng Yeh; Jiun-Long Wang; Kowit-Yu Chong; Chuan-Mu Chen
Journal:  Oncotarget       Date:  2015-04-30

7.  Effect of bovine lactoferrin as a novel therapeutic agent in a rat model of sepsis-induced acute lung injury.

Authors:  Nannan Han; Hengjie Li; Gang Li; Ye Shen; Min Fei; Yong Nan
Journal:  AMB Express       Date:  2019-10-31       Impact factor: 3.298

8.  Oral immunotherapy with the ingestion of house dust mite extract in a murine model of allergic asthma.

Authors:  Yao-Tung Wang; Hsu-Chung Liu; Hui-Chen Chen; Yen-Ching Lee; Tung-Chou Tsai; Hsiao-Ling Chen; Hueng-Chuen Fan; Chuan-Mu Chen
Journal:  Allergy Asthma Clin Immunol       Date:  2018-10-16       Impact factor: 3.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.